PubRank

William Y Kim

Author PubWeight™ 52.78‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003 5.14
2 Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell 2012 3.77
3 Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 2010 3.40
4 Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med 2015 3.00
5 Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A 2005 2.54
6 Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A 2014 2.46
7 Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol Imaging 2003 2.17
8 VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated regulation of SIP1 and snail. Mol Cell Biol 2006 2.03
9 Regulation of endocytosis via the oxygen-sensing pathway. Nat Med 2009 2.00
10 Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol 2011 1.75
11 An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. EMBO Rep 2002 1.71
12 State of the science: an update on renal cell carcinoma. Mol Cancer Res 2012 1.58
13 pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell 2007 1.47
14 CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest 2007 1.45
15 Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 2010 1.37
16 HIF1α and HIF2α independently activate SRC to promote melanoma metastases. J Clin Invest 2013 1.32
17 Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Nat Med 2011 1.31
18 Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. Cancer Discov 2013 1.27
19 Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL. J Cell Mol Med 2011 1.13
20 Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006. Cancer 2013 1.07
21 Dominant-negative HIF-3 alpha 4 suppresses VHL-null renal cell carcinoma progression. Cell Cycle 2007 1.05
22 Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials 2013 0.99
23 Dexamethasone-induced posterior reversible encephalopathy syndrome. J Clin Oncol 2007 0.99
24 Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol Ther 2013 0.98
25 mTOR pathway in renal cell carcinoma. Expert Rev Anticancer Ther 2008 0.96
26 A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urol Oncol 2011 0.95
27 Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. J Clin Invest 2014 0.94
28 HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer. Expert Opin Ther Targets 2010 0.91
29 The next steps in next-gen sequencing of cancer genomes. J Clin Invest 2015 0.91
30 Analysis of von Hippel-Lindau hereditary cancer syndrome: implications of oxygen sensing. Methods Enzymol 2004 0.87
31 A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. Lung Cancer 2010 0.81
32 Stearoyl co-A desaturase 1 as a ccRCC therapeutic target: death by stress. Clin Cancer Res 2013 0.79
33 Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer. BJU Int 2012 0.79
34 Molecular responses to hypoxia: ancient pathways, clinical promises. J Cell Mol Med 2009 0.75
35 Copper(II) Activation of Nitrite: Nitrosation of Nucleophiles and Generation of NO by Thiols. J Am Chem Soc 2016 0.75